<DOC>
	<DOCNO>NCT00697060</DOCNO>
	<brief_summary>Protocol AMP-024 Phase 2 study imexon plus docetaxel patient previously treat lung cancer spread body . Docetaxel approve Food Drug Administration ( FDA ) second line therapy cancer . The imexon administer day 1-5 docetaxel day 1 every 3 week cycle . The objective protocol determine combination imexon plus docetaxel safe effective .</brief_summary>
	<brief_title>A Safety Efficacy Trial Amplimexon Plus Taxotere Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Subjects histologically cytologically confirm NSCLC . 2 . Subject metastatic disease ( Appendix D ) receive 2 prior chemotherapy regimens metastatic disease . Adjuvant chemotherapy consider one prior regimen . Immunological target agent bevacizumab , erlotinib gefitinib consider prior regimen . 3 . Subjects must least one measurable lesion RECIST criterion ( Appendix C ) . If measurable lesion lymph node , must measure least 20 mm LD , target lesion single lesion , cytological histological confirmation NSCLC require . 4 . Resolution chemotherapy radiotherapyrelated toxicity CTCAE grade 1 low , except stable sensory neuropathy &lt; grade 2 and/or alopecia . 5 . Men woman age &gt; 18 year . 6 . ECOG performance status 0 1 ( Appendix E ) . 7 . Not pregnant lactating . 8 . If child bear potential must able agree use adequate contraception . 9 . Adequate renal function define : serum creatinine level &lt; 2.0 mg/dL . 10 . G6PD ( quantitative ) great equal low limit normal . 11 . Adequate hematologic function define : absolute neutrophil count ( ANC ) &gt; 1,500/mm³ , platelet count &gt; 100,000/mm³ , hemoglobin level &gt; 9 g/dL . 12 . Adequate hepatic function define : total bilirubin level &lt; ULN , AST ALT level &lt; 1.5 x ULN Alkaline phosphatase &lt; 2.5x ULN 13 . Prior brain metastasis allow must treat control &gt; 1 month prior steroid . 14 . Subjects willing able comply study protocol duration study . 15 . Able render write informed consent follow protocol requirement . 1 . Subjects receive previous treatment docetaxel . 2 . Subjects receive chemotherapy radiation treatment within 4 week study treatment start . 3 . Prior high dose chemotherapy hematopoietic stem cell rescue within past two year . 4 . Pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen and/or medical management recurrent pleural effusion . 5 . Subjects meningeal carcinomatosis . 6 . Women pregnant breastfeeding , woman child bear potential ( WOCBP ) either positive serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) pregnancy test ; WOCBP unless ( 1 ) surgically sterile ( hysterectomy , bilateral oophorectomy ) ( 2 ) use adequate measure contraception opinion Investigator . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 7 . Severe uncontrolled intercurrent infection illness . 8 . Significant cardiovascular disease include limited history congestive heart failure &gt; NYHA grade II ( Appendix E ) , unstable angina myocardial infarction within past six month , serious uncontrolled arrhythmia . 9 . Subjects organ allograft . 10 . Subjects prior malignancy , carcinoma situ cervix , nonmelanoma skin cancer , superficial bladder cancer unless prior malignancy diagnose definitively treat &gt; 5 year previously subsequent evidence recurrence . 11 . Subjects preexist neuropathy &gt; CTCAE Grade 2 . 12 . Subjects significant disease disorder , opinion Investigator , would exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Previously treat</keyword>
</DOC>